FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308774217> ?p ?o ?g. }

• W4308774217 endingPage "1931" @default.
• W4308774217 startingPage "1931" @default.
• W4308774217 abstract "Myasthenia gravis (MG) is an immune-mediated disorder of the neuromuscular junction. About 10% are refractory to immunosuppressive therapy.To analyze the response of patients with generalized MG to rituximab.A retrospective review of patients with MG who received rituximab was carried out (n = 13, M:F = 6:7, mean age: 44.84 ± 15.73 years). Myasthenia Gravis Foundation of America (MGFA), MGFA post-intervention status (MGFA-PIS), and Myasthenia Gravis Status and Treatment Intensity (MGSTI) were assessed before and after rituximab.The duration of MG was 104.07 ± 92.25 months. Before rituximab, the MGFA was IIA/IIB/IIIA/IIIB/IVB/V in 1/1/2/6/2/1 patients and MGSTI was four in eight patients and six in three patients. The mean duration of follow up was 20.92 ± 14.06 months (range, 4 to 42 months). Dose reduction or discontinuation of cholinesterase inhibitors could be achieved 12 patients. Complete stable remission (CSR) and pharmacologic remission (PR) were achieved in one and four patients respectively and five patients had minimal manifestations. Most patients attained level 0, 1 or 2 MGSTI at last follow up. No rituximab infusion-related adverse events were noted. Three patients had exacerbation of MG between one to five weeks after rituximab administration. Three patients died, one each due to a cardiac event unrelated to MG or treatment, complications related to myasthenic crisis, and coronavirus disease.Rituximab was effective in bringing about remission in MG and can be considered as a first-line agent. However, it has to be administered under close supervision as some patients develop exacerbation of MG akin to steroid-induced worsening." @default.
• W4308774217 created "2022-11-15" @default.
• W4308774217 creator A5002327351 @default.
• W4308774217 creator A5005085166 @default.
• W4308774217 creator A5010531436 @default.
• W4308774217 creator A5035749100 @default.
• W4308774217 creator A5037134200 @default.
• W4308774217 creator A5043502289 @default.
• W4308774217 creator A5050060342 @default.
• W4308774217 creator A5057398774 @default.
• W4308774217 creator A5079412094 @default.
• W4308774217 date "2022-01-01" @default.
• W4308774217 modified "2023-09-26" @default.
• W4308774217 title "Rituximab in Myasthenia Gravis- Experience from a Low- and Middle-Income Country (LMIC) Setting" @default.
• W4308774217 cites W1965772209 @default.
• W4308774217 cites W2021398160 @default.
• W4308774217 cites W2041047359 @default.
• W4308774217 cites W2057882261 @default.
• W4308774217 cites W2073866924 @default.
• W4308774217 cites W2082237468 @default.
• W4308774217 cites W2111680674 @default.
• W4308774217 cites W2124176495 @default.
• W4308774217 cites W2131286564 @default.
• W4308774217 cites W2141231827 @default.
• W4308774217 cites W2163100333 @default.
• W4308774217 cites W2406546229 @default.
• W4308774217 cites W2555422834 @default.
• W4308774217 cites W2560852951 @default.
• W4308774217 cites W2584675601 @default.
• W4308774217 cites W2619783238 @default.
• W4308774217 cites W2742758273 @default.
• W4308774217 cites W2800388833 @default.
• W4308774217 cites W2801527958 @default.
• W4308774217 cites W2805892265 @default.
• W4308774217 cites W2887498089 @default.
• W4308774217 cites W2894367790 @default.
• W4308774217 cites W2900912039 @default.
• W4308774217 cites W2902320022 @default.
• W4308774217 cites W2909823939 @default.
• W4308774217 cites W2923215055 @default.
• W4308774217 cites W2944474952 @default.
• W4308774217 cites W2953460189 @default.
• W4308774217 cites W2967339422 @default.
• W4308774217 cites W2981006094 @default.
• W4308774217 cites W2995171305 @default.
• W4308774217 cites W2998249298 @default.
• W4308774217 cites W3000276814 @default.
• W4308774217 cites W3023124841 @default.
• W4308774217 cites W3025945386 @default.
• W4308774217 cites W3040479952 @default.
• W4308774217 cites W3081066467 @default.
• W4308774217 cites W3093027820 @default.
• W4308774217 cites W3094785429 @default.
• W4308774217 cites W4206172679 @default.
• W4308774217 doi "https://doi.org/10.4103/0028-3886.359277" @default.
• W4308774217 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36352590" @default.
• W4308774217 hasPublicationYear "2022" @default.
• W4308774217 type Work @default.
• W4308774217 citedByCount "1" @default.
• W4308774217 countsByYear W43087742172023 @default.
• W4308774217 crossrefType "journal-article" @default.
• W4308774217 hasAuthorship W4308774217A5002327351 @default.
• W4308774217 hasAuthorship W4308774217A5005085166 @default.
• W4308774217 hasAuthorship W4308774217A5010531436 @default.
• W4308774217 hasAuthorship W4308774217A5035749100 @default.
• W4308774217 hasAuthorship W4308774217A5037134200 @default.
• W4308774217 hasAuthorship W4308774217A5043502289 @default.
• W4308774217 hasAuthorship W4308774217A5050060342 @default.
• W4308774217 hasAuthorship W4308774217A5057398774 @default.
• W4308774217 hasAuthorship W4308774217A5079412094 @default.
• W4308774217 hasConcept C121332964 @default.
• W4308774217 hasConcept C126322002 @default.
• W4308774217 hasConcept C142424586 @default.
• W4308774217 hasConcept C197934379 @default.
• W4308774217 hasConcept C2777014857 @default.
• W4308774217 hasConcept C2778105408 @default.
• W4308774217 hasConcept C2778715236 @default.
• W4308774217 hasConcept C2779338263 @default.
• W4308774217 hasConcept C2780653079 @default.
• W4308774217 hasConcept C71924100 @default.
• W4308774217 hasConcept C87355193 @default.
• W4308774217 hasConcept C90924648 @default.
• W4308774217 hasConceptScore W4308774217C121332964 @default.
• W4308774217 hasConceptScore W4308774217C126322002 @default.
• W4308774217 hasConceptScore W4308774217C142424586 @default.
• W4308774217 hasConceptScore W4308774217C197934379 @default.
• W4308774217 hasConceptScore W4308774217C2777014857 @default.
• W4308774217 hasConceptScore W4308774217C2778105408 @default.
• W4308774217 hasConceptScore W4308774217C2778715236 @default.
• W4308774217 hasConceptScore W4308774217C2779338263 @default.
• W4308774217 hasConceptScore W4308774217C2780653079 @default.
• W4308774217 hasConceptScore W4308774217C71924100 @default.
• W4308774217 hasConceptScore W4308774217C87355193 @default.
• W4308774217 hasConceptScore W4308774217C90924648 @default.
• W4308774217 hasIssue "5" @default.
• W4308774217 hasLocation W43087742171 @default.
• W4308774217 hasLocation W43087742172 @default.
• W4308774217 hasOpenAccess W4308774217 @default.

• next